Skip to content

Accurate diagnosis, screening and treatment of refractory rhinosinusitis

Accurate diagnosis, screening and treatment of refractory rhinosinusitis

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200066851
Enrollment
Unknown
Registered
2022-12-20
Start date
2022-12-20
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Refractory rhinosinusitis

Interventions

Refractory rhinosinusitis group:None
Control group:None

Sponsors

Shanghai Sixth People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
16 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1.Inclusion criteria of CRS Primary symptoms: nasal obstruction, nasal discharge; Secondary symptoms: facial pain/pressure, hyposmia/anosmia; Presence of two or more symptoms above, one of which should be either nasal obstruction or nasal discharge; Patients with appropriate perioperative management and nasal care; Endoscopic signs of: mucopurulent discharge primarily from middle meatus or olfactory cleft, congestion or edema of nasal mucosa, nasal polyps; Imaging changes: sinus CT scan indicates mucosal inflammation in the ostiomeatal complex and/or sinuses; Aged from 16 to 70; with complete record of examinations. 2.Inclusion criteria of RRS CRS patients undergoing endoscopic sinus surgery; CRS patients with appropriate perioperative management and nasal care; Over 3 months of medical treatment after surgery, such as oral or intranasal corticosteroids, antibiotics and nasal irrigation; Persistent symptoms and signs after 6-month follow-up visit; Aged from 16 to 70 with complete record of examinations. 3.Inclusion criteria of the controls Non-CRS patients that will undergo, endonasal skull base surgery, lacrimal duct surgery or septoplasty; Aged from 16 to 70 with complete record of examinations.

Exclusion criteria

Exclusion criteria: antrochoanal polyp, immunodeficiency, coagulation disorders, cystic fibrosis, fungal rhinosinusitis and aspirin allergy

Design outcomes

Primary

MeasureTime frame
Visual analogue scale score;Lund-Mackay score of sinus computed tomography;Lund-Kennedy endoscopic score;Absolute count and percentage of peripheral blood eosinophils;Pathohistologic analysis of nasal mucosa;

Secondary

MeasureTime frame
Expression of IL-13 in nasal mucosa;Expression of IL-17A in nasal mucosa;Expression of IFN-? in nasal mucosa;

Countries

China

Contacts

Public ContactHai Lin

Shanghai Sixth people' hospital

hailin@sjtu.edu.cn18930173556

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026